424 related articles for article (PubMed ID: 32202617)
21. Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer.
Yeong J; Lim JCT; Lee B; Li H; Ong CCH; Thike AA; Yeap WH; Yang Y; Lim AYH; Tay TKY; Liu J; Wong SC; Chen J; Lim EH; Iqbal J; Dent R; Newell EW; Tan PH
J Immunother Cancer; 2019 Feb; 7(1):34. PubMed ID: 30728081
[TBL] [Abstract][Full Text] [Related]
22. Spatial Profiles of Intratumoral PD-1
Yoshimura K; Tsujikawa T; Mitsuda J; Ogi H; Saburi S; Ohmura G; Arai A; Shibata S; Thibault G; Chang YH; Clayburgh DR; Yasukawa S; Miyagawa-Hayashino A; Konishi E; Itoh K; Coussens LM; Hirano S
Front Immunol; 2021; 12():769534. PubMed ID: 34777389
[TBL] [Abstract][Full Text] [Related]
23. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
[TBL] [Abstract][Full Text] [Related]
24. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
[TBL] [Abstract][Full Text] [Related]
25. Immune characterization of breast cancer metastases: prognostic implications.
Dieci MV; Tsvetkova V; Orvieto E; Piacentini F; Ficarra G; Griguolo G; Miglietta F; Giarratano T; Omarini C; Bonaguro S; Cappellesso R; Aliberti C; Vernaci G; Giorgi CA; Faggioni G; Tasca G; Conte P; Guarneri V
Breast Cancer Res; 2018 Jun; 20(1):62. PubMed ID: 29929548
[TBL] [Abstract][Full Text] [Related]
26. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.
Savas P; Virassamy B; Ye C; Salim A; Mintoff CP; Caramia F; Salgado R; Byrne DJ; Teo ZL; Dushyanthen S; Byrne A; Wein L; Luen SJ; Poliness C; Nightingale SS; Skandarajah AS; Gyorki DE; Thornton CM; Beavis PA; Fox SB; ; Darcy PK; Speed TP; Mackay LK; Neeson PJ; Loi S
Nat Med; 2018 Jul; 24(7):986-993. PubMed ID: 29942092
[TBL] [Abstract][Full Text] [Related]
27. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
28. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
29. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
Giraldo NA; Becht E; Vano Y; Petitprez F; Lacroix L; Validire P; Sanchez-Salas R; Ingels A; Oudard S; Moatti A; Buttard B; Bourass S; Germain C; Cathelineau X; Fridman WH; Sautès-Fridman C
Clin Cancer Res; 2017 Aug; 23(15):4416-4428. PubMed ID: 28213366
[No Abstract] [Full Text] [Related]
30. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
31. The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer.
Yan Z; Zhong Z; Shi C; Feng M; Feng X; Liu T
Cancer Biol Ther; 2024 Dec; 25(1):2355705. PubMed ID: 38778753
[TBL] [Abstract][Full Text] [Related]
32. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
Ren X; Wu H; Lu J; Zhang Y; Luo Y; Xu Q; Shen S; Liang Z
Cancer Biol Ther; 2018 May; 19(5):373-380. PubMed ID: 29336717
[TBL] [Abstract][Full Text] [Related]
33. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
Loi S; Dushyanthen S; Beavis PA; Salgado R; Denkert C; Savas P; Combs S; Rimm DL; Giltnane JM; Estrada MV; Sánchez V; Sanders ME; Cook RS; Pilkinton MA; Mallal SA; Wang K; Miller VA; Stephens PJ; Yelensky R; Doimi FD; Gómez H; Ryzhov SV; Darcy PK; Arteaga CL; Balko JM
Clin Cancer Res; 2016 Mar; 22(6):1499-509. PubMed ID: 26515496
[TBL] [Abstract][Full Text] [Related]
34. PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.
Webb JR; Milne K; Nelson BH
Cancer Immunol Res; 2015 Aug; 3(8):926-35. PubMed ID: 25957117
[TBL] [Abstract][Full Text] [Related]
35. Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease.
Zerdes I; Sifakis EG; Matikas A; Chrétien S; Tobin NP; Hartman J; Rassidakis GZ; Bergh J; Foukakis T
Mol Oncol; 2020 May; 14(5):951-963. PubMed ID: 32115850
[TBL] [Abstract][Full Text] [Related]
36. T-cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment.
Cai MC; Zhao X; Cao M; Ma P; Chen M; Wu J; Jia C; He C; Fu Y; Tan L; Xue X; Yu Z; Zhuang G
J Pathol; 2020 Jun; 251(2):147-159. PubMed ID: 32222046
[TBL] [Abstract][Full Text] [Related]
37. Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.
Biton J; Ouakrim H; Dechartres A; Alifano M; Mansuet-Lupo A; Si H; Halpin R; Creasy T; Bantsimba-Malanda C; Arrondeau J; Goldwasser F; Boudou-Rouquette P; Fournel L; Roche N; Burgel PR; Goc J; Devi-Marulkar P; Germain C; Dieu-Nosjean MC; Cremer I; Herbst R; Damotte D
Am J Respir Crit Care Med; 2018 Oct; 198(7):928-940. PubMed ID: 29518341
[TBL] [Abstract][Full Text] [Related]
38. BTN3A2 serves as a prognostic marker and favors immune infiltration in triple-negative breast cancer.
Cai P; Lu Z; Wu J; Qin X; Wang Z; Zhang Z; Zheng L; Zhao J
J Cell Biochem; 2020 Mar; 121(3):2643-2654. PubMed ID: 31692043
[TBL] [Abstract][Full Text] [Related]
39. TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients.
Dadiani M; Necula D; Kahana-Edwin S; Oren N; Baram T; Marin I; Morzaev-Sulzbach D; Pavlovski A; Balint-Lahat N; Anafi L; Wiemann S; Korner C; Gal-Yam EN; Avivi C; Kaufman B; Barshack I; Ben-Baruch A
Cancer Immunol Immunother; 2020 Jul; 69(7):1315-1326. PubMed ID: 32198536
[TBL] [Abstract][Full Text] [Related]
40. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.
Kim YA; Lee HJ; Heo SH; Park HS; Park SY; Bang W; Song IH; Park IA; Gong G
Breast Cancer Res Treat; 2016 Apr; 156(3):597-606. PubMed ID: 27075916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
